BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Highlighted STAT3 as a Potential Drug Target for Cancer Therapy
Sang-Kyu Ye1,*, Haeri Lee1, Ae Jin Jeong1
1Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Korea,
2Ischemic/Hypoxic Disease Institute and 3Neuro-Immune Information Storage Network Research Center and 4Biomedical Science Project (BK21PLUS), Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Abstract
Signal transducer and activator of transcription 3 (STAT3), is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor microenvironment, and present inhibitors of STAT3 signaling cascades.
Abstract, Accepted Manuscript [Submitted on May 30, 2019, Accepted on May 30, 2019]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd